ProCE Banner Activity

Targeted Therapies for HER2-Positive Gastrointestinal Cancers: Experts Answer Your Questions

Clinical Thought

In this commentary, experts answer frequently asked questions about HER2 assessment in gastric, colorectal, and other gastrointestinal cancers and how to use this information to tailor up-to-date treatment strategies. 

Released: July 12, 2023

Share

Faculty

Geoffrey Ku

Geoffrey Ku, MD

Associate Attending Physician
Head, Esophagogastric Section, Gastrointestinal Oncology Service & member, Cellular Therapy Service
Department of Medicine

Kanwal Raghav

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Seagen Inc.

Faculty Disclosure

Primary Author

Geoffrey Ku, MD

Associate Attending Physician
Head, Esophagogastric Section, Gastrointestinal Oncology Service & member, Cellular Therapy Service
Department of Medicine

Geoffrey Ku, MD: researcher: Adaptimmune, AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, Merck, Oncolys, Pieris, Zymeworks; consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Merck, Pieris, Zymeworks.

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Seattle Genetics; researcher (paid to institution): AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Guardant Health, HiberCell, Innovent, Janssen, Merck, Seattle Genetics, UCB Biosciences, Xencor.

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Amgen, Arcus, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Merck, Novartis, Seagen; data safety monitoring board: Mirati, Pfizer.